Health Alert:

Philadelphia Facilities Alert Due to Civil Unrest

See the latest Coronavirus Information including testing sites, visitation restrictions, appointments and scheduling, and more.

Hematologic Malignancies Program

Program Leaders: Edward Stadtmauer, MD and Nancy Speck, PhD

The Hematologic Malignancies Program drives basic scientific discoveries and translates them into novel therapeutics for patients with myeloid and lymphoid neoplasms. Formed in 1994, the Program has two scientific aims:

  • Develop a mechanisms-based understanding of the genetic, cellular, and biochemical processes regulating malignant hematopoiesis
  • Translate basic scientific discoveries into more effective and less toxic therapies for hematologic malignancies

Areas of national expertise include molecular processes (epigenetic, transcriptional, translational, signaling) underlying malignant hematopoiesis; hematopoietic stem cell biology and transplantation; molecular therapeutics; and immune-based therapies. The Program is co-led by Dr. Edward Stadtmauer, an expert in clinical trials of novel therapeutics for hematologic malignancies and blood and marrow transplantation, and Dr. Nancy Speck, an internationally known basic scientist working in the area of hematopoietic stem cells and leukemia. Investments by the Cancer Center include an innovative Hematologic Malignancies Translational Center of Excellence (TCE) co-led by Dr. Stadtmauer, as well as an emerging Lymphoid Malignancy TCE co-led by Drs. Stephen Schuster and Megan Lim. These and other investments galvanize an already successful Program by expanding resources for laboratory, tissue banking, and clinical research and providing pilot grant funding. High impact scientific accomplishments include studies garnering multiple FDA approvals in recent years.

Hematologic Malignancies Program Membership